Literature DB >> 25129312

Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma.

Fan-Long Meng1, Wei Wang, Wei-Dong Jia.   

Abstract

The aim of this study was to explore the diagnostic and prognostic value of serum microRNAs (miRNAs) in hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC). We retrospectively analyzed clinical data of 84 consecutive patients with HBV-related HCC who underwent curative resection. Additionally, we enrolled 46 healthy controls and 31 patients with chronic liver disease (CLD). Serum levels of miR-155-5p, miR-24-3p, miR-490-3p, miR-210-3p, and miR-335-5p were measured. Associations of serum miRNAs with clinicopathological factors were evaluated. Receiver operating characteristic curves were established for discriminating HCC patients from CLD patients, and the area under the curve (AUC) was calculated. Overall survival (OS) and disease-free survival (DFS) were examined by the Kaplan-Meier method. Prognostic factors were determined by multivariate Cox analysis. Consequently, serum miR-24-3p levels were significantly greater in HCC patients than healthy controls and CLD patients. Serum miR-24-3p was significantly associated with vascular invasion in HCC patients. Serum miR-24-3p discriminated HCC patients from CLD, with an AUC of 0.636 [95 % confidence interval (CI) 0.524-0.748]. Combined serum alpha-fetoprotein (AFP) and miR-24-3p had an increased AUC of 0.834 (95 % CI 0.745-0.923; P < 0.001). Elevated serum miR-24-3p was an independent poor prognostic factor for OS and DFS of HCC patients. In conclusion, the combination of serum miR-24-3p and AFP improves the diagnostic accuracy for HCC prediction compared to each biomarker alone. High serum miR-24-3p level is an independent predictor of poor OS and DFS in patients with HBV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25129312     DOI: 10.1007/s12032-014-0177-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  31 in total

1.  Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma.

Authors:  Ya-Hui Huang; Kwang-Huei Lin; Hua-Chien Chen; Ming-Ling Chang; Chao-Wei Hsu; Ming-Wei Lai; Tse-Ching Chen; Wei-Chen Lee; Yi-Hsin Tseng; Chau-Ting Yeh
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

Review 2.  How microRNAs control cell division, differentiation and death.

Authors:  Eric A Miska
Journal:  Curr Opin Genet Dev       Date:  2005-10       Impact factor: 5.578

3.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).

Authors:  Evan M Kroh; Rachael K Parkin; Patrick S Mitchell; Muneesh Tewari
Journal:  Methods       Date:  2010-02-08       Impact factor: 3.608

4.  Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.

Authors:  Tindara Franchina; Valeria Amodeo; Giuseppe Bronte; Giuseppina Savio; Giuseppina R R Ricciardi; Maria Picciotto; Antonio Russo; Antonio Giordano; Vincenzo Adamo
Journal:  J Cell Physiol       Date:  2014-01       Impact factor: 6.384

5.  Downregulation of miR-122 in the rodent and human hepatocellular carcinomas.

Authors:  Huban Kutay; Shoumei Bai; Jharna Datta; Tasneem Motiwala; Igor Pogribny; Wendy Frankel; Samson T Jacob; Kalpana Ghoshal
Journal:  J Cell Biochem       Date:  2006-10-15       Impact factor: 4.429

Review 6.  MicroRNA and cancer: Current status and prospective.

Authors:  Wei Wu; Miao Sun; Gang-Ming Zou; Jianjun Chen
Journal:  Int J Cancer       Date:  2007-03-01       Impact factor: 7.396

7.  Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma.

Authors:  J Qi; J Wang; H Katayama; S Sen; S M Liu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

8.  microRNA-205 regulates HER3 in human breast cancer.

Authors:  Marilena V Iorio; Patrizia Casalini; Claudia Piovan; Gianpiero Di Leva; Andrea Merlo; Tiziana Triulzi; Sylvie Ménard; Carlo M Croce; Elda Tagliabue
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

9.  Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma.

Authors:  Osamu Dohi; Kohichiroh Yasui; Yasuyuki Gen; Hisashi Takada; Mio Endo; Kazuhiro Tsuji; Chika Konishi; Nobuhisa Yamada; Hironori Mitsuyoshi; Nobuaki Yagi; Yuji Naito; Shinji Tanaka; Shigeki Arii; Toshikazu Yoshikawa
Journal:  Int J Oncol       Date:  2012-11-30       Impact factor: 5.650

10.  MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis.

Authors:  Yi-Xiao Liu; Xi-Dai Long; Zhi-Feng Xi; Yun Ma; Xiao-Ying Huang; Jin-Guang Yao; Chao Wang; Tian-Yu Xing; Qiang Xia
Journal:  Biomed Res Int       Date:  2014-04-08       Impact factor: 3.411

View more
  26 in total

1.  miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.

Authors:  Laurent Ehrlich; Chad Hall; Julie Venter; David Dostal; Francesca Bernuzzi; Pietro Invernizzi; Fanyin Meng; Jerome P Trzeciakowski; Tianhao Zhou; Holly Standeford; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-01-11       Impact factor: 4.307

2.  Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.

Authors:  Lin Chen; Feihu Chu; Yali Cao; Jianguo Shao; Feng Wang
Journal:  Tumour Biol       Date:  2015-04-24

3.  Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies.

Authors:  Jing Shen; Abby B Siegel; Helen Remotti; Qiao Wang; Regina M Santella
Journal:  Hepatoma Res       Date:  2016-06-01

Review 4.  Versatile role of miR-24/24-1*/24-2* expression in cancer and other human diseases.

Authors:  Sanjukta Mukherjee; Bhagyashree Shelar; Sudhir Krishna
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

Review 5.  MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma.

Authors:  Sirio Fiorino; Maria Letizia Bacchi-Reggiani; Michela Visani; Giorgia Acquaviva; Adele Fornelli; Michele Masetti; Andrea Tura; Fabio Grizzi; Matteo Zanello; Laura Mastrangelo; Raffaele Lombardi; Luca Di Tommaso; Arrigo Bondi; Sergio Sabbatani; Andrea Domanico; Carlo Fabbri; Paolo Leandri; Annalisa Pession; Elio Jovine; Dario de Biase
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

6.  MicroRNA-23a/24-2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta-analysis.

Authors:  Jing Quan; Suyue Liu; Kangfu Dai; Lu Jin; Tao He; Xiang Pan; Yongqing Lai
Journal:  Mol Clin Oncol       Date:  2017-11-08

7.  Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance.

Authors:  L Yang; Q Xu; H Xie; G Gu; J Jiang
Journal:  Clin Transl Oncol       Date:  2015-11-19       Impact factor: 3.405

8.  Prognostic significance of microRNA miR-24 in cancers: a meta-analysis.

Authors:  Rongqiang Liu; Weihao Kong; Shiyang Zheng; Chenyu Yu; Yajie Yu; Yuling Xu; Linsen Ye; Yi Shao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

9.  Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.

Authors:  Jun Li; Zhang-Jun Cheng; Yang Liu; Zhen-Lin Yan; Kui Wang; Dong Wu; Xu-Ying Wan; Yong Xia; Wan Yee Lau; Meng-Chao Wu; Feng Shen
Journal:  Oncotarget       Date:  2015-04-20

10.  MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer.

Authors:  Shiyu Zhang; Cheng Liu; Xuan Zou; Xiangnan Geng; Xin Zhou; XingChen Fan; Danxia Zhu; Huo Zhang; Wei Zhu
Journal:  PeerJ       Date:  2021-05-19       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.